Evaluation of maternal serum sestrin-2 levels in intrauterine growth restriction
Irish Journal of Medical Science, cilt.192, sa.5, ss.2259-2264, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 192 Sayı: 5
- Basım Tarihi: 2023
- Doi Numarası: 10.1007/s11845-023-03329-2
- Dergi Adı: Irish Journal of Medical Science
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, CAB Abstracts
- Sayfa Sayıları: ss.2259-2264
- Anahtar Kelimeler: Fetal growth retardation, Oxidative stress, Pregnancy, Sestrins
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Background: Sestrin-2 (SESN2) is a antioxidant protein that can be activated by a number of conditions, including DNA damage and hypoxia. Aims: Our objective was to evaluate maternal serum SESN2 levels in patients with intrauterine growth restriction (IUGR) and its association with adverse perinatal outcomes. Methods: This prospective study included a total of 87 pregnant women admitted to our tertiary care center between 2018 August and 2019 July. The study group consisted of a total of 44 patients who had been diagnosed with IUGR. Forty-three low-risk and gestational age-matched pregnant women were taken as control group. Demographic data, maternal serum SESN2 levels, and maternal-neonatal outcomes were evaluated. SESN2 levels were analyzed by the enzyme-linked immunosorbent assay (ELISA) method and compared between groups. Results: Maternal serum SESN2 levels were significantly higher in the IUGR group compared to control group (22.38 ng/ml vs. 13.0 ng/ml, p < 0.001). In correlation analysis, a negative significant correlation was found between SESN2 levels and gestational week at delivery (r = − 0.387, p < 0.001). The ideal cut-off value for detecting IUGR was 9.5 ng/ml, and the area under the curve was 0.719 (95%CI: 0.610–0.827). Birth interval, gestational week at birth, birth weight, and 1–5-min Apgar scores were lower in the IUGR group (p < 0.001). Conclusions: Maternal serum SESN2 levels are elevated in IUGR and are associated with adverse neonatal outcome. Considering that SESN2 is involved in pathogenesis, it can be used as a new marker for the evaluation of IUGR.